Tagamet GERD indication
Executive Summary
SmithKline Beecham will begin marketing Tagamet (cimetidine) for treatment of erosive gastroesophageal reflux disease (GERD) diagnosed by endoscopy in late May, following receipt of FDA approval March 7. Glaxo's Zantac and Robins' Reglan already are approved for GERD. FDA approved Tagamet tablet, liquid and injection forms for "healing of lesions and control of symptoms." The Gastrointestinal Drugs Advisory Committee approval recommendation last October came 14 years after SB's initial NDA filing in 1976 ("The Pink Sheet" Oct. 29, p. 12).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth